Statins may cause symptoms of onset Parkinson’s disease to advance more quickly in those who are susceptible to the disease, according to a new study published in Movement Disorders.
Statins may cause symptoms of onset Parkinson’s disease to advance more quickly in those who are susceptible to the disease, according to a new study published in Movement Disorders.
Researchers at Penn State College of Medicine investigated previous inconsistent research that suggested the use of statins could protect against Parkinson’s disease while treating high cholesterol. The inconsistent results could be because of the 2 types of statins—water-soluble statins that cannot enter the brain, and fat-soluble statins that can.
“One of the reasons that may have explained these prior inconsistent results is that higher cholesterol, the main indication to use statins, has been related to lower occurrence of Parkinson’s disease,” Xuemei Huang, professor of neurology, said in a statement. “This made it hard to know if the statin protective effect was due to the drug or preexisting cholesterol status.”
The researchers used a database of insurance claims to analyze the data for those with Parkinson’s disease. They identified 22,000 patients with Parkinson’s disease and of them, 2322 patients were recently diagnosed with the disease. From here, the researchers paired every patient with Parkinson’s to a control group member. Data was reported according to which patients had taken a statin and the amount of time before a symptom of Parkinson’s was noticed.
The results led the researchers to conclude that statin use and higher risk of Parkinson’s disease are related, and the symptoms are more apparent following the use of the statin.
“Statin use was associated with higher, not lower, Parkinson’s disease risk, and the association was more noticeable for lipophilic statins, an observation inconsistent with the current hypothesis that these statins protect nerve cells,” stated Huang. “In addition, this association was most robust for use of statins less than 2-and-a-half years, suggesting that statins may facilitate the onset of Parkinson’s disease.”
The research mentions a previous study that found that patients who stopped using statins have a greater chance of having Parkinson’s disease. This would lead to the conclusion that statins protect against Parkinson’s. However, the Penn State College of Medicine accounts for this by claiming that patients stop using stations because of their Parkinson’s disease symptoms.
“We are not saying that statins cause Parkinson’s disease, but rather that our study suggests that statins should not be used based on the idea that they will protect against Parkinson’s,” concludes Huang.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More